PALI | Palisade Bio, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	3.80 - 4.12
52 Week Range	3.30 - 22.35
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	72,449
Average Volume	64,109
Shares Outstanding	1,184,490
Market Cap	4,655,046
Sector	Healthcare
Industry	Biotechnology
IPO Date	2007-03-30

Valuation
Profitability
Growth
Health
P/E Ratio	-0.21
Forward P/E Ratio	N/A
EPS	-18.57
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	9
Country	USA
Website	PALI

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or due to surgery. The company was founded in 2005 and is headquartered in Carlsbad, California.

PALI's peers: ADTX, ATNF, ATOS, ATXI, VINO, CYTO, EDSA, CELZ, IBIO, INAB, INM, KPRX, NBTX, NBY, ORMP, ZURA, IMMX, ENVB, EFTR, VIRI, NAVB, ZVSA, PHIO, UNCY, APGN, PSTV, SNGX, TCBP, TNXP, VRPX, WINT, XBIO, ERNA, ICU, SPRY, CARM

*Chart delayed

Analyzing fundamentals for PALI we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is poor, Growth is desperately bad and Health is weak. For more detailed analysis please see PALI Fundamentals page.

Watching at PALI technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on PALI Technicals page.